Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Heather Leasure

Nurse Practitioner, Family Rockford, IL Nurse Practitioner

NPI 1700326220 CMS profile 10960497

2902 McFarland Rd Ste 100, Rockford, IL 61107

Open in the dashboard

General payments

$8,788

363 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heather Leasure of Rockford, IL is reported in the CMS Open Payments database as having received $8,788 across 363 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,761 74
2024 General $1,742 80
2023 General $1,566 78
2022 General $2,399 73
2021 General $1,320 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heather Leasure
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Heather Leasure were reported at $1,761. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Heather Leasure Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,320 $124 $35–$379 $132
2022 $2,399 $141 $44–$430 $149
2023 $1,566 $154 $49–$476 $160
2024 $1,742 $165 $51–$504 $164
2025 $1,761 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,098 55 payments
  2. Pacira Pharmaceuticals Incorporated $882 9 payments
  3. Nevro Corp. $827 36 payments
  4. Collegium Pharmaceutical, Inc. $703 46 payments
  5. Amgen Inc. $699 22 payments
  6. BIOTRONIK NRO, Inc. $677 20 payments
  7. Abbott Laboratories $470 23 payments
  8. Pfizer Inc. $385 26 payments
  9. Boston Scientific Corporation $375 12 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $369 10 payments
  11. Other $2,303 104 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,192 361 payments
  2. Travel and Lodging $596 2 payments
Products named General payments · program years 2021–2025
  1. Iovera $882 9 payments
  2. UBRELVY $793 39 payments
  3. QULIPTA $610 27 payments
  4. NURTEC ODT Primary Care $566 15 payments
  5. Omnia $416 19 payments
  6. Senza $411 17 payments
  7. NURTEC ODT Pain $385 26 payments
  8. BELBUCA $327 21 payments
  9. XTAMPZA $321 21 payments
  10. Prospera $317 11 payments
  11. Other $4,421 206 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

16,433

Median for Nurse Practitioner: 389

Drug cost

$1,164,103

Median for Nurse Practitioner: $21,885

Branded share of claims

44.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 249 $210,086
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 4,597 $147,200
Nucynta Er Tapentadol Hcl Brand 63 $115,922
Oxycontin Oxycodone Hcl Brand 114 $114,318
Fentanyl Generic 836 $89,622
Buprenorphine Generic 255 $61,754
Belbuca Buprenorphine Hcl Brand 77 $49,867
Hysingla Er Hydrocodone Bitartrate Brand 53 $46,498
Pregabalin Generic 1,135 $33,694
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 828 $33,620

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$148,367

Of which drugs: $8,246

Medicare patients

512

Average age 71

Services billed

5,074

345 women, 167 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 71%
Depression 39%
Diabetes 34%
Chronic kidney disease 31%
COPD 25%
Ischemic heart disease 24%
Osteoporosis 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Infusion, normal saline solution , 1000 cc J7030 Office 11 56 $89

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $146
$146 — —
NURTEC ODT
  • PFIZER INC. $139
$139 17 —
QULIPTA
  • AbbVie, Inc. $121
$121 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $114
$114 77 —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $92
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

363 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record